Spain
Nuage Therapeutics, a biopharma startup established in 2021 and headquartered in Spain, has emerged as a pioneer in the development of selective and potent drugs for targeting intrinsically disordered proteins. As a spin-off from the acclaimed Institute for Research in Biomedicine (IRB Barcelona) and ICREA, the company leverages innovative approaches in biomolecular condensation and chemical biology to address critical unmet medical needs.
Their strategic focus on challenging indications within the biotech landscape positions them as a key player among emerging pharmaceutical companies. The involvement of the State Research Agency signals investor confidence, as evidenced by their recent €2.70M Early VC investment on 01 December 2025. As Nuage Therapeutics continues to advance drug discovery, their progress in the biopharma sector holds substantial promise for future growth and investor returns.
